Literature DB >> 11508682

Bile acid reflux and possible inhibition of Helicobacter pylori infection in subjects without gastric surgery.

Y Kawai1, S Tazuma, M Inoue.   

Abstract

Bile acids are generally known to inhibit growth of Helicobacter pylori in vitro, but whether they do so in humans with no gastric surgery has been uncertain. The present study addresses this issue. Among healthy control subjects with preserved acid secretion, H. pylori-positive subjects were older and had lower gastric bile acid concentrations than H. pylori-negative subjects (P < 0.05). Among gastric ulcer patients with preserved acid secretion, H. pylori-positive patients had a higher basal acid output than H. pylori-negative patients (P < 0.05). Among H. pylori-positive subjects with preserved acid secretion, duodenal ulcer patients had a higher basal and maximum acid output than healthy control subjects (P < 0.01). In conclusion, gastric bile acids may suppress initial stages of H. pylori infection in subjects without gastric surgery. However gastric bile acids may have little effect on peptic ulcer disease, once H. pylori infection is established.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11508682     DOI: 10.1023/a:1010678210019

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  23 in total

1.  Helicobacter pylori infection, gastric acid secretion, and infant growth.

Authors:  A Dale; J E Thomas; M K Darboe; W A Coward; M Harding; L T Weaver
Journal:  J Pediatr Gastroenterol Nutr       Date:  1998-04       Impact factor: 2.839

2.  Gastric juice ammonia vs CLO test for diagnosis of Helicobacter pylori infection.

Authors:  D H Yang; H S Bom; Y E Joo; S K Choi; J S Rew; C M Yoon
Journal:  Dig Dis Sci       Date:  1995-05       Impact factor: 3.199

Review 3.  H. pylori and cagA: relationships with gastric cancer, duodenal ulcer, and reflux esophagitis and its complications.

Authors:  D Y Graham; Y Yamaoka
Journal:  Helicobacter       Date:  1998-09       Impact factor: 5.753

4.  Prospective comparative study of the influence of postoperative bile reflux on gastric mucosal histology and Campylobacter pylori infection.

Authors:  G J Offerhaus; P N Rieu; J B Jansen; H J Joosten; C B Lamers
Journal:  Gut       Date:  1989-11       Impact factor: 23.059

5.  Possible role of Helicobacter pylori infection in early gastric cancer development.

Authors:  M Asaka; T Kimura; M Kato; M Kudo; K Miki; K Ogoshi; T Kato; M Tatsuta; D Y Graham
Journal:  Cancer       Date:  1994-06-01       Impact factor: 6.860

6.  Healthy controls have as much bile reflux as gastric ulcer patients.

Authors:  N E Schindlbeck; C Heinrich; F Stellaard; G Paumgartner; S A Müller-Lissner
Journal:  Gut       Date:  1987-12       Impact factor: 23.059

7.  Helicobacter pylori infection and abnormalities of acid secretion in patients with duodenal ulcer disease.

Authors:  E M el-Omar; I D Penman; J E Ardill; R S Chittajallu; C Howie; K E McColl
Journal:  Gastroenterology       Date:  1995-09       Impact factor: 22.682

Review 8.  Campylobacter pylori and peptic ulcer disease.

Authors:  D Y Graham
Journal:  Gastroenterology       Date:  1989-02       Impact factor: 22.682

9.  High prevalence and persistence of cytotoxin-positive Helicobacter pylori strains in a population with high prevalence of atrophic gastritis.

Authors:  J G Fox; P Correa; N S Taylor; N Thompson; E Fontham; F Janney; M Sobhan; B Ruiz; F Hunter
Journal:  Am J Gastroenterol       Date:  1992-11       Impact factor: 10.864

10.  Effect of duodenal ulcer surgery and enterogastric reflux on Campylobacter pyloridis.

Authors:  H J O'Connor; M F Dixon; J I Wyatt; A T Axon; D C Ward; E P Dewar; D Johnston
Journal:  Lancet       Date:  1986-11-22       Impact factor: 79.321

View more
  1 in total

Review 1.  Bile Reflux Gastritis: Insights into Pathogenesis, Relevant Factors, Carcinomatous Risk, Diagnosis, and Management.

Authors:  Xiaolan Shi; Zijiao Chen; Yi Yang; Su Yan
Journal:  Gastroenterol Res Pract       Date:  2022-09-12       Impact factor: 1.919

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.